CA2193531C - Procede de preparation du trihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yle - Google Patents

Procede de preparation du trihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yle Download PDF

Info

Publication number
CA2193531C
CA2193531C CA002193531A CA2193531A CA2193531C CA 2193531 C CA2193531 C CA 2193531C CA 002193531 A CA002193531 A CA 002193531A CA 2193531 A CA2193531 A CA 2193531A CA 2193531 C CA2193531 C CA 2193531C
Authority
CA
Canada
Prior art keywords
beta
alpha
tax
acetoxy
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002193531A
Other languages
English (en)
French (fr)
Other versions
CA2193531A1 (fr
Inventor
Jean-Rene Authelin
Jacques Doveze
Elie Fouque
Bernadette Mandard
Isabelle Taillepied
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2193531(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CA2193531A1 publication Critical patent/CA2193531A1/fr
Application granted granted Critical
Publication of CA2193531C publication Critical patent/CA2193531C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA002193531A 1994-07-08 1995-07-07 Procede de preparation du trihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yle Expired - Lifetime CA2193531C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9408479A FR2722191B1 (fr) 1994-07-08 1994-07-08 Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
FR94/08479 1994-07-08
PCT/FR1995/000910 WO1996001815A1 (fr) 1994-07-08 1995-07-07 PROCEDE DE PREPARATION DU TRIHYDRATE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YLE

Publications (2)

Publication Number Publication Date
CA2193531A1 CA2193531A1 (fr) 1996-01-25
CA2193531C true CA2193531C (fr) 2006-12-05

Family

ID=9465183

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002193531A Expired - Lifetime CA2193531C (fr) 1994-07-08 1995-07-07 Procede de preparation du trihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yle

Country Status (38)

Country Link
US (1) US6022985A (show.php)
EP (1) EP0770070B1 (show.php)
JP (1) JP3753155B2 (show.php)
KR (1) KR100391753B1 (show.php)
CN (1) CN1067996C (show.php)
AT (1) ATE171702T1 (show.php)
AU (1) AU706519B2 (show.php)
BR (1) BR9508789A (show.php)
CA (1) CA2193531C (show.php)
CO (1) CO4410189A1 (show.php)
CZ (1) CZ284695B6 (show.php)
DE (1) DE69505128T2 (show.php)
DK (1) DK0770070T3 (show.php)
DZ (1) DZ1905A1 (show.php)
ES (1) ES2121404T3 (show.php)
FI (1) FI119246B (show.php)
FR (1) FR2722191B1 (show.php)
GR (1) GR3027558T3 (show.php)
HU (1) HU220634B1 (show.php)
IL (1) IL114274A (show.php)
IN (1) IN183947B (show.php)
IS (1) IS2032B (show.php)
MA (1) MA23606A1 (show.php)
MX (1) MX9700173A (show.php)
MY (1) MY118481A (show.php)
NO (1) NO314500B1 (show.php)
NZ (1) NZ289455A (show.php)
PE (1) PE8697A1 (show.php)
PL (1) PL179876B1 (show.php)
RU (1) RU2126397C1 (show.php)
SI (1) SI0770070T1 (show.php)
SK (1) SK280520B6 (show.php)
TN (1) TNSN95071A1 (show.php)
TW (1) TW419473B (show.php)
UA (1) UA51624C2 (show.php)
UY (1) UY23991A1 (show.php)
WO (1) WO1996001815A1 (show.php)
ZA (1) ZA955646B (show.php)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010020342A (ko) 1997-04-28 2001-03-15 자끄 사비나 종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
US6266619B1 (en) * 1999-07-20 2001-07-24 Halliburton Energy Services, Inc. System and method for real time reservoir management
US6853921B2 (en) 1999-07-20 2005-02-08 Halliburton Energy Services, Inc. System and method for real time reservoir management
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6891050B2 (en) * 2001-08-10 2005-05-10 Dabur India Limited Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs
US6881852B2 (en) * 2002-02-05 2005-04-19 Dabur India Limited Process of purification of paclitaxel and docetaxel
US7247738B2 (en) * 2002-05-07 2007-07-24 Dabur India Limited Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6838569B2 (en) * 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
US7584165B2 (en) * 2003-01-30 2009-09-01 Landmark Graphics Corporation Support apparatus, method and system for real time operations and maintenance
US8703982B2 (en) * 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
US7838551B2 (en) 2003-12-12 2010-11-23 Quiral Quimica do Basil S.A. Process for the preparation of concentrated, sterile injectable solutions containing docetaxel
US7142986B2 (en) * 2005-02-01 2006-11-28 Smith International, Inc. System for optimizing drilling in real time
CN100420681C (zh) * 2005-04-29 2008-09-24 上海奥锐特国际贸易有限公司 多烯紫杉醇三水物的制备方法
LT1931321T (lt) 2005-08-31 2019-05-10 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir antimikrobinius agentus
KR101643416B1 (ko) * 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
BRPI0606132A2 (pt) * 2005-10-12 2009-06-02 Sicor Inc formas cristalinas de docetaxel e processos para seu preparo
KR100995390B1 (ko) 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
US8280635B2 (en) * 2006-01-20 2012-10-02 Landmark Graphics Corporation Dynamic production system management
EP2001874A4 (en) * 2006-03-21 2010-04-07 Reddys Lab Ltd Dr DOCETAXEL POLYMORPH AND CORRESPONDING METHODS
CN101534642A (zh) * 2006-10-20 2009-09-16 神隆药业新加坡私人有限公司 用于制备结晶无水多西紫杉醇的方法
KR100868116B1 (ko) * 2007-04-09 2008-11-10 한미약품 주식회사 도세탁셀·모노프로필렌글라이콜 내포화합물 및 이의제조방법
KR100878455B1 (ko) * 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
WO2009006590A2 (en) * 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
EP2080763A1 (en) * 2008-01-18 2009-07-22 INDENA S.p.A. Crystalline form I of ortataxel
EP2080764B1 (en) 2008-01-18 2012-08-22 INDENA S.p.A. Solid forms of ortataxel
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
WO2012160568A1 (en) * 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph
WO2013036795A2 (en) 2011-09-08 2013-03-14 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
MX360092B (es) 2012-04-04 2018-10-19 Halozyme Inc Terapia de combinación con un agente antihialuronano y un taxano orientado a tumor.
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2968406A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai WITH AUTOLOGOUS TUMORLYSAT-LOADED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides

Also Published As

Publication number Publication date
FI119246B (fi) 2008-09-15
CZ284695B6 (cs) 1999-02-17
PL179876B1 (pl) 2000-11-30
TNSN95071A1 (fr) 1996-02-06
BR9508789A (pt) 1997-10-21
EP0770070A1 (fr) 1997-05-02
HU9700041D0 (en) 1997-02-28
FI970069L (fi) 1997-01-07
IS4411A (is) 1997-01-07
IN183947B (show.php) 2000-05-20
ZA955646B (en) 1996-02-21
SK280520B6 (sk) 2000-03-13
NO970007L (no) 1997-01-02
DE69505128D1 (de) 1998-11-05
DZ1905A1 (fr) 2002-02-17
IS2032B (is) 2005-08-15
KR970704721A (ko) 1997-09-06
IL114274A (en) 1999-04-11
TW419473B (en) 2001-01-21
FR2722191A1 (fr) 1996-01-12
DE69505128T2 (de) 1999-04-01
WO1996001815A1 (fr) 1996-01-25
HU220634B1 (hu) 2002-03-28
KR100391753B1 (ko) 2004-02-11
ES2121404T3 (es) 1998-11-16
HUT76833A (en) 1997-11-28
MY118481A (en) 2004-11-30
JPH10502627A (ja) 1998-03-10
CA2193531A1 (fr) 1996-01-25
ATE171702T1 (de) 1998-10-15
FI970069A0 (fi) 1997-01-07
FR2722191B1 (fr) 1996-08-23
AU706519B2 (en) 1999-06-17
GR3027558T3 (en) 1998-11-30
JP3753155B2 (ja) 2006-03-08
DK0770070T3 (da) 1999-03-01
CO4410189A1 (es) 1997-01-09
UA51624C2 (uk) 2002-12-16
SK697A3 (en) 1997-06-04
MA23606A1 (fr) 1996-04-01
NO314500B1 (no) 2003-03-31
MX9700173A (es) 1997-04-30
CZ3597A3 (en) 1997-04-16
PE8697A1 (es) 1997-03-26
SI0770070T1 (en) 1998-12-31
US6022985A (en) 2000-02-08
CN1151741A (zh) 1997-06-11
EP0770070B1 (fr) 1998-09-30
RU2126397C1 (ru) 1999-02-20
NO970007D0 (no) 1997-01-02
IL114274A0 (en) 1995-10-31
NZ289455A (en) 1997-12-19
CN1067996C (zh) 2001-07-04
UY23991A1 (es) 1995-09-20
AU2930595A (en) 1996-02-09
PL318195A1 (en) 1997-05-26

Similar Documents

Publication Publication Date Title
CA2193531C (fr) Procede de preparation du trihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1,7.beta.,10.beta.-trihydroxy-9-oxo-tax-11-en-13.alpha.-yle
EP0056766A1 (fr) Procédé de préparation d'amino-4 chloroquinoléines
BE1008403A4 (fr) Procede de cristallisation d'iopamidol.
EP0913374A1 (fr) Procédé d'obtention de la forme polymorphe epsilon de l'hexanitrohexaazaisowurtzitane
FR2468577A1 (fr) Nouveaux 5z,8z,11z,14z,17z-eicosapentaenoates d'alkylphenyle, utiles notamment comme inhibiteurs de l'agglomeration des plaquettes sanguines et agents antisecretoires
EP0805806B1 (fr) Procede de preparation du trihydrate du (2r,3s)-3-benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy-2alfa-benzoyloxy-beta,20-epoxy-beta-dihydroxy-9-oxo-tax-11-en-beta-yle
FR2467185A1 (fr) Procedes de separation et de purification du resorcinol et de l'hydroquinone
EP0145618B1 (fr) Procédé de préparation de la N,N'-bis(hydroxy-2 ethyl)oxamide
LU85292A1 (fr) Procede pour la preparation de 1,8-dihydroxy-10-acyl-9-anthrones,en particulier pour une utilisation dans le traitement du psoriasis
CH671766A5 (show.php)
BE1017609A4 (fr) Forme polymorphe epsilon d'un derive de l'isowurtzitane et procede de synthese.
CA2689466A1 (fr) Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
FR2589469A1 (fr) Procede de preparation de l'acide valproique
EP0876361B1 (fr) Dihydrate du (2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1-hydroxy-9-oxo-19-nor-cyclopropa g]tax-11-ene-13alpha-yle, et son procede de preparation
CH343407A (fr) Procédé de préparation de peptides
WO2025145066A1 (en) An improved process for preparation of ethiodized oil
FR2467835A1 (fr) Procede de separation et d'epuration de l'anthracene de l'huile d'anthracene
BE491159A (show.php)
FR2471384A1 (fr) Procede de preparation de tartrate d'ergotamine
CH337827A (fr) Procédé de préparation d'un complexe cristallisable de l'aldéhyde 2,6-trans, trans de la vitamine A
FR2830864A1 (fr) Forme polymorphe beta d'un derive de l'isowurtzitane et procede de synthese
CH357062A (fr) Procédé pour la préparation de la cyanoformamide
FR2508448A1 (fr) Monohydrate de cimetidine et procede pour sa preparation
CH282871A (fr) Procédé de préparation du sel sodique de pénicilline cristallisé.
BE832067A (fr) Procede perfectionne de synthese du 1-(tetrahydro-2-furannyl) -5-fluorouracile.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150707